 김인호 교수 E-mail : kim_dajung@hanmail.net |
|
연구분야 조혈모세포이식 (동종, 자가) 악성혈액종양 (림프종, 다발골수종, 백혈병, 골수형성이상증후군) 양성혈액질환 (재생불량빈혈, 면역관련 혈액질환) |
|
학력사항 - 1983-1985 Seoul National University College of Arts and Sciences, Korea - 1985-1992 Seoul National University College of Medicine, Korea (MD) - 2000-2002 Seoul National University Graduate School, Korea (MS) - 2002-2006 Inha University Graduate School, Korea (PhD) |
|
경력사항 - 1992-1993 Rotating Intern, Seoul National University Hospital, Korea - 1993-1997 Resident in Medicine, Seoul National University Hospital, Korea - 1997-1998 Chief, Department of Medicine, Ulleung Medical Center, Korea - 1998-2000 Member, Preparation Committee for Establishment of Korean National Cancer Institute - 2000-2001 Fellow in Hematology/Oncology, Seoul National University Hospital, Korea - 2001-2003 Instructor in Medicine, Inha University Hospital. Korea - 2003-2005 Assistant Professor, Inha University Hospital, Korea - 2005- Professor, Seoul National University Hospital, Korea |
|
주요 연구물 (1) 조혈모세포이식에 관한 임상연구 1. Lee YG, Kim I, Lee E, Bang SM, Kang CH, Kim YT, Kim HJ, Wu HG, Kim YW, Kim TM, Lee KW, Lee SH, Kim DW, Heo DS. Risk factors and prognostic impact of venous thromboembolism in Asian patients with non-small cell lung cancer. Thromb Haemost. 2014 Jan 30. doi: 10.1160/TH13-11-0956. [Epub ahead of print] PubMed PMID: 24477503 ISSN: 0340-6245 SCI (As a Corresponding author) 2. Koh Y, Lee SY, Kim I, Kwon JH, Yoon SS, Park S, Chung MH, Suh SY, Kim KS, Kim HS. Bortezomib-associated peripheral neuropathy requiring medical treatment is decreased by administering the medication by subcutaneous injection in Korean multiple myeloma patients. Cancer Chemother Pharmacol. 2014 Aug 6. doi: 10.1007/s00280-014-2555-0. PMID: 25096796 (As a Corresponding author) 3. Bae JY, Kim JW, Kim I. Low-dose 1,25-dihydroxyvitamin D3 combined with arsenic trioxide synergistically inhibits proliferation of acute myeloid leukemia cells by promoting apoptosis. Oncol Rep. 2013 May 9. doi: 10.3892/or.2013.2444. [Epub ahead of print] PubMed PMID: 23660868. (As a Corresponding author) 4. Lee YG, Kim I, Yoon SS, Park S, Cheong JW, Min YH, Lee JO, Bang SM, Yi HG, Kim CS, Park Y, Kim BS, Mun YC, Seong CM, Park J, Lee JH, Kim SY, Lee HG, Kim YK, Kim HJ. Comparative analysis between azacitidine and decitabine for the treatment of myelodysplastic syndromes. Br J Haematol. 2013 May;161(3):339-47. doi: 10.1111/bjh.12256. Epub 2013 Feb 21. PubMed PMID: 23432512. (As a Corresponding author) 5. Shin DY, Kim I, Kim JH, Lee YG, Kang EJ, Cho HJ, Lee KH, Kim HJ, Park EH, Lee JE, Bae JY, See CJ, Yoon SS, Park SS, Han KS, Park MH, Hong YC, Park S, Kim BK. RANTES polymorphisms and the risk of graft-versus-host disease in human leukocyte antigen-matched sibling allogeneic hematopoietic stem cell transplantation. Acta Haematol. 2013;129(3):137-45. doi: 10.1159/000343273. Epub 2012 Nov 30. PubMed PMID: 23207898. (As a Corresponding author) 6. Kim I, Koh Y, Yoon SS, Park S, Kim BK, Kim DY, Lee JH, Lee KH, Cheong JW, Lee HK, Kim SH, Kim H, Joo YD, Lee SM, Won JH, Park SK, Hong DS, Kim SH, Sohn SK, Kim CS, Park E, Kim MK, Park MR, Lee JH, Min YH; Korean Society of Hematology AML/MDS working party. Fludarabine, cytarabine, and attenuated-dose idarubicin (m-FLAI) combination therapy for elderly acute myeloid leukemia patients. Am J Hematol. 2013 Jan;88(1):10-5. doi: 10.1002/ajh.23337. Epub 2012 Oct 17. PubMed PMID: 23077109.(as a first author) |
